Advertisement

Topics

Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX2-73

11:28 EDT 19 Oct 2018 | Investing News Network

Anavex Life Sciences (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that the Company has received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) is … Continued

The post Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX2-73 appeared first on Investing News Network.

Original Article: Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX2-73

NEXT ARTICLE

More From BioPortfolio on "Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX2-73"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...